Clinical Trial Update: A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 study of amrubicin in relapsed or refractory thymic malignancies has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma
• Thymus Cancer

Drugs mentioned

• Amrubicin (amrubicin)

Snippet

Sponsor: Heather Wakelee | Conditions: Thymoma, Thymus Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-14